Research programme: neurodegenerative disorder therapeutics - Guangdong Maijinjia Biotechnologies/Servier
Alternative Names: Blockmir candidates - Guangdong Maijinjia Biotechnologies/ServierLatest Information Update: 03 Nov 2021
At a glance
- Originator Guangdong Maijinjia Biotechnologies; Servier
- Class Antisense oligonucleotides
- Mechanism of Action Gene expression stimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodegenerative disorders
Most Recent Events
- 07 Oct 2021 Servier enters into a collaboration and exclusive license option agreement with Guangdong Maijinjia Biotechnologies to develop a therapy for neurodegenerative disorders
- 07 Oct 2021 Early research in Neurodegenerative disorders in China (Parenteral)
- 07 Oct 2021 Early research in Neurodegenerative disorders in France (Parenteral)